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S278 Poster Session IIinfection whit gB1+gB3 and gB2 + gB3. HCMV disease devel-
oped in 2 patients, characterized for gastrointestinal disease and
these two patients had infection with a mixture of HCMV gB
genotypes.
Conclusions: in this study the most prevalent genotype in patients
with HCMV active infection was gB genotype 1 and moreover, the
mixture of HCMV gB genotypes was associate with gastrointestinal
disease. However, this study is limited due to the small number of
patients, thus making it difficult to draw a firm conclusion regard-
ing the distribution of HCMV genotypes and their possible associ-
ation with outcome. Nevertheless, these results may be taken as
a preliminary report on the prevalence of different HCMV gB ge-
notypes in a Brazilian allogeneic HSCT population with active
HCMV infection.323
A PHASE I STUDY OF CLOFARABINE PLUS HIGH DOSE MELPHALAN AS A
CONDITIONING REGIMEN FOR ALLOGENEIC TRANSPLANTATION
Kirschbaum, M.H., Stein, A.S., Nakamura, R., Auayporn, N.,
Popplewell, L., Delioukina, M., Chen, R., Snyder, D., Conrad, J.,
Frankel, P., Forman, S.J. City of Hope National Cancer Center, Duarte,
CA
Background:Reduced intensity regimens for allo transplant suc-
cessfully replaced the alkylating agent cyclophosphamide with
the purine nucleoside antimetabolite, fludarabine, an immuno-
suppressive with a milder toxicity profile. Clofarabine is a purine
nucleoside analogue designed to exploit a double halogen strat-
egy which confers resistance to adenosine deaminase and makes
the drug more efficient than fludarabine at inhibiting ribonucle-
otide reductase and disrupting mitochondrial function, leading
to apoptosis.
Aims:To evaluate a clofarabine containing regimen as conditioning
for allogeneic stem cell transplant.
Methods: phase I dose escalation: clofarabine (dose level
one5 30 mg/m2, dose level two and three5 40 mg/m2) IV daily
days –7 to day –3 infused over 30 minutes IV, plus Melphalan
(dose level one and two, 100 mg/m2, dose level three, 140 mg/
m2) administered over 30 minutes IV on day –2. Related or un-
related allogeneic stem cells were infused on day 0. GVHD
prophylaxis: initially CSP plus mycophenelate, then tacrolimus
plus sirolimus was adopted as per COH standard of care. Pa-
tients age$ 18 years with AML, ALL, MDS in CR1, CR2 or
in relapse (up to 50% marrow blasts), not deemed eligible for
standard transplant regimens, or at high risk for relapse, are
eligible.
Results: We report on the first 2 dose levels. 10 eligible pa-
tients, all with AML, have been treated thus far, 4 Males, 6 Fe-
males, with a median age of 62 years (39 – 65). 5 patients were
in CR1, 2 patients were in CR2, and 3 patients were trans-
planted in relapse. Grade 3 non-hematologic toxicities included
fatigue, elevation of AST and LFT, diarrhea, and hyponatremia
and mucositis (in one patient). No dose limiting toxicities
(DLT) were seen in level one. One patient in dose level 2
died prior to engraftment due to hepatic, renal, and infectious
toxicities; that dose level has been expanded thus far to seven
patients and no further DLT have been seen (one accrued pa-
tient was ineligible due to mismatch). Three patients in relapse
received an unrelated donor graft, had complete engraftment
and achieved remission. Engraftment data is presented in the
table below. Mild acute skin graft versus host disease (GvHD)
was seen in two patients, with mild gut GvHD responsive to
steroids seen in one patient, and mild chronic GvHD in one
patient.
Conclusion: The combination of clofarabine and melphalan is an
adequate conditioning regimen leading to complete engraftment of
allogeneic stem cells.Dose Days* to Days* to Months
Level Patient ANC$ 0.5x109/L PLT$ 100 Follow-up** Status1 1 14 15 20 Remission
1 2 14 13 20 Remission
1 3 24 23 18 Remission
2 4*** 1 Expired
2 5 13 13 16 Remission
2 6 17 13 10 Remission
2 7 12 14 8 Remission
2 8 16 14 6 Remission
2 10 12 13 1 Remission
2 11 16 15 1 Remissionmedian 14 14 9* - From Transplant ** - Days from transplant to relapse/death or last
contact *** - Patient expired prior to engraftment.324
DYSGLYCEMIA FOLLOWING GLUCOCORTICOID THERAPY FOR ACUTE
GRAFT VS. HOST DISEASE ADVERSELY AFFECTS TRANSPLANTATION
OUTCOMES
Pidala, J.1, Kim, J.2, Alsina, M.1, Ayala, E.1, Field, T.1, Fernandez, H.1,
Kharfan-Dabaja,M.1, Ochoa, L.1, Perez, L.1, Perkins, J.1, Tomblyn,M.1,
Anasetti, C.1 1Moffitt Cancer Center, Tampa, FL; 2Moffitt Cancer Cen-
ter, Tampa, FL
Disordered glucose metabolism is a common complication of glu-
cocorticoid therapy for acute graft vs. host disease (aGVHD) after al-
logeneic hematopoietic cell transplantation (HCT). We aimed to
examine the independent impact of serum glucose parameters (max-
imum,minimum,mean, and standard deviation) on outcomes in a se-
ries of 173 recipients of HCTwho were treated with glucocorticoids
for aGVHD.Median onset of aGVHDwas 23 days (range 5 – 1112).
Patients were treated with primarily 1 mg/kg of glucocorticoids for
biopsy-confirmed aGVHD. The median duration of glucocorticoid
therapywas 271 days (range 15 – 1632).Glucose valueswere obtained
from glucocorticoid initiation date to death or last follow up, result-
ing in a total of 13,170 values. Themedian (range) values for each pa-
rameter were: maximum 292 mg/dL (128 – 694), minimum 75 mg/
dL (34 – 142), mean 146 mg/dL (86 – 327), and standard deviation
47 mg/dL (12 – 108). Baseline diabetes mellitus predicted signifi-
cantly greater maximum, mean, and standard deviation. With a me-
dian follow up of 18 months, median overall survival (OS) was 16
months (95% CI 11 – 34). On multivariable analysis, maximum glu-
cose significantly predicted OS and non-relapse mortality (NRM).
Increased variability also predicted OS and NRM. Those with mini-
mum glucose values of (0 – 60 mg/dL) had increased NRM. Values
for minimum glucose demonstrated a non-linear relationship with
OS: those with minimum glucose of (0 – 60 mg/dL) as well as those
(81 – 150 mg/dL) had significantly worsened OS compared to (61 –
80 mg/dL). Minimum glucose of (81 – 150 mg/dL) was associated
with significantly increased risk for relapse. These data demonstrate
the adverse effect of dysglycemia in patients treated with glucocorti-
coids for aGVHD, and argue for stringent glycemic control in this
setting. Further efforts to reduce the burden of aGVHD, and its as-
sociated treatment with glucocorticoids are paramount.325
ALLOGENEIC HEMATOPOIETIC STEM TRANSPLANTATION DOES NOT
ERASE THE IMPACT OF THE NEW PROGNOSIS CLASSIFICATION IN AML
AND THE NEGATIVE INFLUENCE OF EVI1 AND FLT3 ITD MUTATIONS
Michallet, M., Sobh, M., Hayette, S., Charlot, C., El Hamri, M.,
Tedone, N., Nicolini, F.E., Ducastelle, S., Baracco, F., Tigaud, I.,
Thomas, X. Edouard Herriot Hospital, Lyon, France
We studied 78 patients who underwent an allogeneic HSCT for
AML and for whom we had cytogenetics and molecular markers.
